• General Aspects of Neuroscience Drug Discovery and Development
• 55 min
  1. Is there a role for academia in drug discovery

  • Dr. Adrian J. Ivinson
• 33 min
  2. Receptor-channel research at the interface between academia and pharma

  • Prof. Mihaly Hajos
• Seizure Disorders
• 35 min
  3. Discovery of Levetiracetam (Keppra(R)): The first SV2A ligand for the treatment of epilepsy

  • Dr. Henrik Klitgaard
• 47 min
  4. Anti-seizure drugs: discovery and development

  • Dr. Roger Porter
• Alzheimer's Disease
• 54 min
  5. Abeta toxicity 1

  • Prof. Colin L. Masters
• 28 min
  6. Abeta toxicity 2

  • Prof. Colin L. Masters
• 68 min
  7. Targeting Aß oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer’s disease

  • Prof. William L. Klein
• 19 min
  8. Pathogenic mechanisms and therapeutic approaches for the tauopathies

  • Prof. Karen Duff
• 31 min
  9. Update on fluid biomarkers for neurodegenerative diseases

  • Prof. Henrik Zetterberg
• Parkinson's Disease
• 51 min
  10. Disease-modifying therapies for Parkinson's disease

  • Dr. Todd Sherer
• Schizophrenia
• 20 min
  11. Discovery of schizophrenia drug targets from DISC1 mechanisms

  • Prof. Atsushi Kamiya
• 33 min
  12. Animal models for schizophrenia

  • Dr. Mikhail Pletnikov
• Archived Lectures *These may not cover the latest advances in the field
• 23 min
  13. Biomarkers for Alzheimer's disease

  • Prof. Henrik Zetterberg

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Agenda
3. The need for disease-modifying therapies in PD
4. Parkinson's disease: defining the need (1)
5. Parkinson's disease: defining the need (2)
6. Promising therapeutic targets and pathways
7. Developing disease-modifying therapies
8. LRRK2 is a high priority therapeutic target
9. PD mutations in LRRK2 increase kinase activity
10. Alpha-synuclein linked to PD pathology & genetics
11. Genetics has pointed to other therapeutic targets
12. Neurorestorative approaches have potential for PD
13. Bringing nigral neurons back on line
14. Efficacy of neurotrophic factor therapy in PD
15. Cell replacement therapy - potential of stem cells
16. Targeting general pathophysiological pathways
17. Cellular pathways have been linked to PD (1)
18. Efficacy of pioglitazone in a PD model
19. Cellular pathways have been linked to PD (2)
20. Targeting cell death pathways
21. Isradipine is neuroprotective in PD animal model
22. Cep-1347 has no disease-modifying effect
23. Challenges for clinical translation and testing
24. Biomarkers needed to improve PD modifying trials
25. Need for biomarkers: the Azilect example
26. Different biomarkers needed to improve trials
27. PD biomarkers need to be verified and validated
28. Qualifying and validating biomarkers for trials
29. Parkinson's Progression Markers Initiative (PPMI)
30. PPMI overview
31. PPMI study details: synopsis
32. PPMI governance and structure
33. PPMI steering committee and study cores
34. PPMI funding partners
35. Quality control is a strict focus for data input
36. Ensuring data/samples can be easily accessed
37. Summary of PPMI status and challenges
38. PD pipeline is showing promise

Topics Covered

• The need for disease-modifying therapies for Parkinson's disease
• Promising targets and pathways
• Genetics
• Neurorestoration
• Implicated biochemical pathways
• Challenges for clinical translation and testing
• Need for Biomarkers
• The Parkinson's Progression Markers Initiative

Links

Series:

• Drug Discovery and Development in the Neurosciences

Categories:

• Biochemistry
• Cell Biology
• Clinical Practice
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on March 28, 2013

Financial Disclosures

• Dr. Todd Sherer has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.